Search results
Results from the Tech24 Deals Content Network
Orlistat, sold under the brand name Xenical among others, is a medication used to treat obesity. Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.
Examples of such medications include the Orlistat, which was first prescribed in 1998. In 2009, it became an over-the-counter drug after obtaining consent from the European Medicines Agency. In clinical trials, patients prescribed with Orlistat (120 mg) showed better weight loss than those without (8.76 kg vs 5.81 kg) in one year.
Cetilistat is a drug designed to treat obesity. It acts in the same way as the older drug orlistat (Xenical) by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested.
Use an ice pack or cold compress. Cold therapy can help reduce how much pain you experience after you have tooth surgery, according to a 2019 study. Using an ice pack or cold compress on the area ...
e. Orlistat (Xenical), the most commonly used medication to treat obesity and sibutramine (Meridia), a medication that was withdrawn due to cardiovascular side effects. Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control excess body fat. These medications alter one of the fundamental processes of ...
The trial included more than 17,600 adults ages 45 and up with heart disease who got either a weekly 2.4-milligram dose of semaglutide, which is the drug used in Wegovy, or a placebo.About three ...
It is strongly dose-dependent: for the immediate release preparation, the seizure incidence is 0.4% at the dose 300–450 mg per day; the incidence climbs almost ten-fold for the higher than recommended dose of 600 mg. [23] For comparison, the incidence of unprovoked seizure in the general population is 0.07–0.09%, and the risk of seizure for ...
Etoricoxib. Etoricoxib, sold under the brand name Arcoxia, is a selective COX-2 inhibitor developed and commercialized by Merck. It is approved in 63 countries worldwide as of 2007, except the United States where the Food and Drug Administration sent a Non Approvable Letter to Merck and required them to provide additional data.